Sravankumar Gunda, J Pharmacovigilance 2014, 2:5
http://dx.doi.org/10.4172/2329-6887.S1.015

OMICS Group Conferences
Accelerating Scientific Discovery

3rd International Conference and Exhibition on
Pharmacovigilance & Clinical Trials
October 27-29, 2014 Hyderabad International Convention Centre, India

Friendly reporting system in pharmacovigilance: MAERS

Sravankumar Gunda
Synowledge PV Services India Ltd. , India

Pharmacovigilance plays a major impact on public health, reducing patients, increasing quality of life and decreasing risk factors of the drugs. Under current conditions the Adverse Drug Reactions (ADR) are reported less than 7%, when compared to the occurrence of the ADR's. According to an survey conducted by WHO, in developed countries (like US, UK, France, Germany and Australia) it was reported that about 65% of the HCP's are not interested to report any ADR's due to lack of time & facilities and in developing countries this scenario is a lot worse because of weak reporting systems, lack of proper laws and health authorities. A study conducted with the help of 25 HCP's (healthcare professional) in UK from different hospitals and healthcare centres regarding the ADR system. This study was conducted online, which concluded that due to lack of time and proper facilities, ADR's were not reported by the HCP's. In order to make the process easy, development of mobile application would really help the HCP's for reporting ADR's. This application can be downloaded in android, ios or windows software in any multimedia mobile or a tablet. This application is user friendly, with only four pages to fill.

Page 1: New complaint, verification of your compliant and suggestions to the company

Page 2: Reporter Identification

Page 3: Patient details

Page 4: Drug information

Page 5: Event description and document attachment

The complaint first reaches to the common mail box which is controlled by the application (MAERS) holder and from there it will be distributed to the individual company folders (like GSK, Pfizer, Ranbaxy and etc, based on the product manufacture). The complaint will be then distributed to the concerned MAH or manufacturing company of the country where the drug was manufactured, along with a duplicate copy to the concerned health authority. The ADR's once registered in MAERS will have an UIC (unique identification code) by which the reporter can track the case. This MAERS is a quick and translucent way of reporting between companies, health authorities, reporter and patient's for a better human survival.

Biography

Sravankumar Gunda completed Masters in Analytical Chemistry at Teesside University. He started this carrier as a Pharmacist technician in 2012 and moved on to Product Market programmer by the end of 2012. He is a registered Pharmacist at Andhra Pradesh pharmacist council (India). He is currently working at Synowledge PV services as Drug Safety Associate from Mar 2013.

sravankumar09@gmail.com